All News

The Food and Drug Administration (FDA) approved the use of Lumoxiti (moxetumomab pasudotox-tdfk) for patients with relapsed or refractory hairy cell leukemia (HCL) who previously had at least two prior systemic therapies, including treatment with a purine nucleoside analog.

As a testicular cancer survivor, self-care through exercise is very important to me.

A study published in Blood demonstrated the significant disparities found between insurance status and survival outcomes in patients of all ages with follicular lymphoma.

The words celebrities use carry an enormous amount of weight.

The Food and Drug Administration (FDA) granted priority review to Keytruda (pembrolizumab) monotherapy for the first-line treatment of patients with locally advanced or metastatic nonsquamous or squamous non-small cell lung cancer (NSCLC) whose tumors express PD-L1 without EGFR or ALK genomic tumor aberrations.

One oncology nurse developed the BARF scale so her young patients could better communicate how they were feeling.

I poignantly remember an eloquent wife of a patient who died of acute leukemia shared her analogy with me. She stated, “You know when my dog died, I got a card from my vet. When my husband died, I got nothing.”

A guy with breast cancer sees surviving in a new light.

Two-time cancer survivor encourages fellow survivors to develop resilience to cope with cancer.

Previously, there were concerns that older patients would not be able to handle the toxicities of the procedure, or that their stem cells, which are older, would not work as well. But that proved to not be the case.

The "cancer card" is one of the only upsides to being diagnosed with cancer... but when does it go too far?

A few thoughts and simple methods for finding a way to get back to the center of a life that includes all the emotions

A small study showed that, despite national guideline recommendation, conversations between doctors and patients about the benefits and harms of lung cancer screening in those who are at high risk are not happening the way they should be.

My hope is that more parents and caregivers find the benefits that yoga can offer for children with cancer.

CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, will launch its first television commercial featuring curetoday.com during the Stand Up To Cancer (SU2C) telecast tonight.

I felt like cancer had forced me to do other "uncomfortable" things instead of the bucket list I had chosen.

After success in the non-small cell lung cancer space, immunotherapy is finally making waves in the treatment of small cell lung cancer.

This infographic explains some of the basics on mantle cell lymphoma, a type of non-Hodgkin lymphoma.

By treating the patient as a whole, we ensure the common gaps in care do not get overlooked and the burden of cancer is reduced.

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.

Have you ever wondered "why me" when diagnosed with cancer?

What is a cancer survivor's responsibility? How can she make a difference in the world?

A cancer diagnosis can threaten to shake our understanding of who we are if we let it. Learn how to avoid this trap with some practical advice.

A new tool that helps surgeons distinguish healthy tissue from tumor in real-time could change the landscape of surgical ovarian cancer treatment for the better.

Researchers may have found a potential new way to treat patients with ovarian or lung cancer who had previously failed other treatments, according to early trial findings published in Annals of Oncology.

Perhaps the last thing anybody wants to think about during chemo is a sewer system. If you live in a rural area, however, getting advice about how to pamper your septic system can be helpful.

Take a look at the top 5 CURE stories of August 2018 in this video.

The Food and Drug Administration (FDA) granted priority review to a new supplemental biologics license application for Keytruda (pembrolizumab) to treat adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, according to Merck, the agent’s manufacturer.

One of the things I think about is the future. All cancer patients know we have two futures: One where things go well, and one where they don't.